Navigation Links
New Label Changes for Commonly Prescribed HIV Drug Invirase
Date:10/21/2010

SILVER SPRING, Md., Oct. 21 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that new safety information has been added to the label for the HIV antiviral drug Invirase (saquinavir), describing potentially life-threatening side effects on the heart when used with Norvir (ritonavir), another HIV antiviral medication.

(Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

In February 2010, the agency warned patients and health care professionals that when used together, the two drugs could cause prolongation of the QT and PR intervals--indicators of heart rhythm activity seen on an electrocardiogram.

Prolongation of the QT interval may lead to a condition known as torsades de pointes, an abnormal heart rhythm. With torsades de pointes, patients may experience lightheadedness, fainting or abnormal heart beats. In some cases, torsades de pointes may progress to a life-threatening irregular heart beat known as ventricular fibrillation.

Prolongation of the PR interval may also lead to an abnormal heart rhythm known as heart block. With heart block, patients may experience lightheadedness, fainting or abnormal heartbeats.

The FDA is also requiring a medication guide for patients using Invirase that will describe these potential risks. Patients at greater risk of developing one of the serious heart events described above include those with underlying heart conditions or those that have existing heart rate or rhythm problems.

"These heart conditions could potentially be life-threatening and we want to assure that health care providers and patients are adequately informed of the risks," said Edward Cox, M.D., M.P.H, director, Office of Antimicrobial Products in FDA's Center for Drug Evaluation and Research. "Patients should talk to their doctor if they have any concerns about their treatment. Certain drugs may interact with Invirase and increase the risk of developing these side effects, so patients should be sure to tell their doctor about other medicines they may be taking, including non-prescription medicines, vitamins, and herbal supplements."

Patients and health care professionals should report any side effects from the use of Invirase to the FDA's MedWatch program: http://www.fda.gov/safety/MedWatch/default.htm

Invirase is an antiretroviral medication first approved in 1995, and used in combination with Norvir and other antiretroviral medicines to treat HIV in adults. Invirase does not cure HIV infection, may not prevent development of HIV-related illnesses and may not prevent the spread of HIV to other people.

Invirase is marketed by San Francisco-based Genentech, a subsidiary of the Roche Group. Norvir is marketed by Abbott Laboratories based in Abbott Park, Ill.

For more information:

FDA: Drug Safety Communication: Invirase labels now contain updated risk information on abnormal heart rhythms

http://www.fda.gov/Drugs/DrugSafety/ucm230096.htm

HHS: AIDS News and Resources

http://www.aids.gov/

Media Inquiries: Erica Jefferson, 301-796-4988, erica.jefferson@fda.hhs.gov

Consumer Inquiries: 888-INFO-FDA


'/>"/>
SOURCE U.S. Food and Drug Administration
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amgen to Review Results From TREAT and Propose Updates to ESA Labeling for Chronic Renal Failure Patients at an FDA Advisory Committee Meeting Today
2. Lead Plaintiffs Attorney In Forest Pharmaceuticals Case Says $313 Million Award Is Tip of the Iceberg of Future Off-Label Marketing Lawsuits
3. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
4. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
5. Teva Admits to Making False Statements in US Gianvi™ Label and Agrees to Corrective Measures
6. FRC Urges FDA to Reject New Abortion Drug Falsely Labeled as an Emergency Contraceptive
7. FDA Updates U.S. Product Labels for LABA-Containing Medications Including AstraZenecas SYMBICORT
8. GSK Announces Revised Product Labels for Serevent® and Advair®
9. FDA Approves Labeling Change for Vyvanse(R) (lisdexamfetamine dimesylate) Capsules CII to Include Supplemental Data Demonstrating Significant Efficacy at Two Hours Through 14 Hours After Administration in Adults with ADHD
10. Two Johnson & Johnson Subsidiaries to Pay Over $81 Million to Resolve Allegations of Off-Label Promotion of Topamax
11. Pharmaceutical Giant AstraZeneca to Pay $520 Million for Off-Label Drug Marketing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/15/2017)... OCEANSIDE, Calif. , Aug. 15, 2017  AOTI Inc. announced ... Advanced Oxygen Therapy Inc., has recently opened a New York City ... the ever-increasing usage of its unique Topical Wound Oxygen (TWO 2 ... approved by the Accreditation Commission for Health Care (ACHC) under the ... ...
(Date:8/10/2017)... 2017  Physical Rehabilitation Network (PRN), acquired the long-standing outpatient ... Colorado . The reputable clinic will continue to be ... with his staff of four clinicians. Lipkin received his doctorate ... over 10 years of experience with a strong background in ... marks the 10th PRN clinic in and around the ...
(Date:8/7/2017)... Insightin Health, provider of data-driven decision-making ... announced the selection of Michael Wood ... as of February 2017. In this role, Wood will ... our clients. Wood brings with him more than ... analytics within the healthcare industry. Wood formerly served ...
Breaking Medicine Technology:
(Date:8/17/2017)... ... 2017 , ... Advice Media, the industry leader in digital marketing for medical practices, has been ... been included in the Inc. 5000 for the second time in two years. Shawn Miele, ... Inc. 5000 rankings for the second year in a row. It’s extremely difficult to make ...
(Date:8/17/2017)... ... 17, 2017 , ... A recent report indicates that circa 79 percent of ... deficiencies in data integrity. The FDA outlines their expectations for quality critical instrumentation in ... part of the Beckman Coulter Life Sciences Virtual Trade Show Virtual Event, ...
(Date:8/16/2017)... ... August 16, 2017 , ... The next Patient Care Academy at Kalamazoo Valley ... who successfully complete the seven-week long Patient Care Academy are eligible to take the ... salary for a CNA in Kalamazoo is $24,428.* , As a CNA, one is ...
(Date:8/16/2017)... ... August 16, 2017 , ... Greenfield Advisors is honored to be named to ... second year in a row. The Inc. 5000 list honors private businesses across the ... on the list once is a great accomplishment, but for us to be included ...
(Date:8/16/2017)... (PRWEB) , ... August 16, 2017 , ... Any ... Inc. 5000. The company ranked #4429 on the newly released, 36th annual Inc. ... represents a unique look at the most successful companies within the American economy’s most ...
Breaking Medicine News(10 mins):